MDSpire - Summary
FDA & Government News

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Share

Upcoming FDA decisions in April could lead to significant advancements across various specialties, including neurology, nephrology, endocrinology, and infectious diseases. Notable reviews include GTx-104 for treating aneurysmal subarachnoid hemorrhage, AXS-05 for Alzheimer's disease agitation, and sparsentan for focal segmental glomerulosclerosis. Additionally, teplizumab aims to delay type 1 diabetes progression in young children, while doravirine/islatravir is under consideration for HIV-1 treatment in adults. These decisions may enhance patient outcomes significantly.

Original Source(s)

FDA Monthly Preview: Key April Decisions to Watch

  • by Kathryn Wighton

  • March 31, 2026

Related Content

Meat Intake, APOE Status Linked to Cognitive Aging

Long-term cohort data suggest genotype-specific associations with cognition, not dementia interaction

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

Surgical Approaches Evolve in Tremor Syndromes

Evidence review highlights expanding role of neuromodulation and lesioning, with differences across tremor types